Get the Stockscreener App
9.17
0.55%
0.05
Tango Therapeutics Inc stock is traded at $9.17, with a volume of 1.44M.
It is up +0.55% in the last 24 hours and up +15.64% over the past month.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
See More
Previous Close:
$9.12
Open:
$9.12
24h Volume:
1.44M
Relative Volume:
0.46
Market Cap:
$1.23B
Revenue:
$24.30M
Net Income/Loss:
$-145.57M
P/E Ratio:
-6.8947
EPS:
-1.33
Net Cash Flow:
$-149.17M
1W Performance:
-4.18%
1M Performance:
+15.64%
6M Performance:
+105.15%
1Y Performance:
+177.04%
1-Day Range:
$9.00
$9.34
1-Week Range:
$8.88
$10.22
52-Week Range:
$1.03
$11.20
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics Inc
Sector
Industry
Phone
(857) 320-4900
Address
201 BROOKLINE AVENUE, BOSTON
Compare TNGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
9.17 | 1.23B | 24.30M | -145.57M | -149.17M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-17-24 | Initiated | Jefferies | Buy |
| Apr-04-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-24 | Initiated | Piper Sandler | Overweight |
| Dec-08-23 | Initiated | B. Riley Securities | Buy |
| Oct-20-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-20-21 | Initiated | SVB Leerink | Outperform |
View All
Tango Therapeutics Inc Stock (TNGX) Latest News
Vivo Capital LLC Purchases Shares of 600,000 Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics, Inc. $TNGX Stock Holdings Trimmed by XTX Topco Ltd - MarketBeat
Can Tango Therapeutics (TNGX) Climb 37.28% to Reach the Level Wall Street Analysts Expect? - Zacks Investment Research
Tango Therapeutics CFO Beckman sells $25,281 in stock - MSN
Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 32% - simplywall.st
Geode Capital Management LLC Grows Position in Tango Therapeutics, Inc. $TNGX - MarketBeat
How interest rate cuts could boost Tango Therapeutics Inc. stockMarket Risk Analysis & Daily Profit Focused Screening - Newser
Stifel Initiates Coverage of Tango Therapeutics (TNGX) with Buy Recommendation - Nasdaq
Is Tango Therapeutics Inc. stock near bottom after declineJuly 2025 Spike Watch & Long-Term Safe Return Strategies - Newser
Stifel initiates Tango Therapeutics stock with Buy rating, $15 price target - Investing.com Nigeria
Stifel initiates Tango Therapeutics stock with Buy rating, $15 price target By Investing.com - Investing.com South Africa
Piper Sandler Healthcare Conference - marketscreener.com
Virtus Investment Advisers LLC Sells 38,979 Shares of Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics (TNGX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Can Tango Therapeutics Stock Hold Up When Markets Turn? - Trefis
Retail Trends: How interest rate cuts could boost Tango Therapeutics Inc stockRecession Risk & Fast Exit Strategy with Risk Control - BỘ NỘI VỤ
Tango Therapeutics Inc trading resumes - MSN
Tango Therapeutics Stock Soars Pre-Market On $225M Financing, Positive Study Data For Cancer Therapy - MSN
Tango Therapeutics initiated with a Peer Perform at Wolfe Research - MSN
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Tango Therapeutics launches $100M at-the-market stock offering - MSN
Wall Street Analysts See a 46.07% Upside in Tango Therapeutics (TNGX): Can the Stock Really Move This High? - MSN
Tango Therapeutics (NASDAQ:TNGX) Hits New 52-Week HighTime to Buy? - MarketBeat
Novavax, UniFirst, and More Stocks See Action From Activist Investors - Barron's
Tango Therapeutics stock hits 52-week high at 9.7 USD By Investing.com - Investing.com Nigeria
Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal TestingBuy (TNGX) - Seeking Alpha
Tango Therapeutics stock hits 52-week high at 9.7 USD - Investing.com India
Tango Therapeutics launches new $100 million at-the-market stock offering By Investing.com - Investing.com Nigeria
Tango Therapeutics Inc files for mixed shelf offeringSEC filing - marketscreener.com
Tango Therapeutics files prospectus for resale of 1.7 million shares by selling stockholderSEC filing - marketscreener.com
Tango Therapeutics launches new $100 million at-the-market stock offering - Investing.com Nigeria
Tango Therapeutics Enters New Sales Agreement with Leerink - TipRanks
[S-3] Tango Therapeutics, Inc. Shelf Registration Statement | TNGX SEC FilingForm S-3 - Stock Titan
[8-K] Tango Therapeutics, Inc. Reports Material Event | TNGX SEC FilingForm 8-K - Stock Titan
Why Tango Therapeutics Inc. stock remains on watchlists2025 Historical Comparison & Reliable Volume Spike Alerts - newser.com
Short interest data insights for Tango Therapeutics Inc.Weekly Trade Review & Accurate Intraday Trade Tips - newser.com
How analysts rate Tango Therapeutics Inc. stock todayWeekly Profit Analysis & Growth Focused Investment Plans - newser.com
TNGX: Pivotal pancreatic cancer study advances, with strong combo data and cash runway into 2028 - TradingView
Will Tango Therapeutics Inc. stock benefit from automationForecast Cut & Short-Term Trading Alerts - newser.com
TNGX: Vopimetostat advances in pivotal and combo studies, with strong efficacy and cash runway into 2028 - TradingView
Tango Therapeutics Inc Stock (TNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):